Biomx Financials
PHGE Stock | USD 0.61 0.01 1.67% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Net Profit Margin | 157 | 84.3 |
|
| |||||
Debt Equity Ratio | 4.63 | 4.41 |
|
| |||||
Current Ratio | 1.72 | 1.81 |
|
|
The essential information of the day-to-day investment outlook for Biomx includes many different criteria found on its balance sheet. An individual investor should monitor Biomx's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Biomx.
Net Income |
|
Biomx | Select Account or Indicator |
Please note, the presentation of Biomx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomx's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomx's management manipulating its earnings.
Biomx Stock Summary
Biomx competes with ZyVersa Therapeutics, Immix Biopharma, Cns Pharmaceuticals, and Sonnet Biotherapeutics. BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. Biomx operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 103 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NYSE MKT Exchange |
ISIN | US09090D1037 |
CUSIP | 09090D103 09090D301 15957A108 |
Location | New York; U.S.A |
Business Address | 22 Einstein Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.biomx.com |
Phone | 972 7 2394 2377 |
Currency | USD - US Dollar |
Biomx Key Financial Ratios
Return On Equity | -0.38 | ||||
Revenue | (357 K) | ||||
EBITDA | (22.82 M) | ||||
Net Income | (26.17 M) | ||||
Cash Per Share | 1.53 X |
Biomx Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 70.4M | 78.0M | 45.5M | 25.0M | 28.8M | 48.7M | |
Other Current Liab | 3.9M | 7.0M | 1.6M | 3.3M | 3.8M | 2.9M | |
Other Liab | 585K | 701K | 215K | 2.2M | 2.5M | 2.6M | |
Net Tangible Assets | 42.8M | 84.5M | 57.5M | 46.0M | 52.9M | 53.3M | |
Net Debt | (30.6M) | (42.1M) | (12.0M) | (772K) | (694.8K) | (729.5K) | |
Retained Earnings | (72.3M) | (108.5M) | (136.8M) | (163.0M) | (146.7M) | (139.3M) | |
Accounts Payable | 2.3M | 2.8M | 820K | 1.4M | 1.6M | 1.2M | |
Cash | 36.5M | 62.1M | 31.3M | 15.9M | 18.2M | 25.6M | |
Net Receivables | 276K | (108K) | 567K | 574K | 660.1K | 693.1K | |
Other Current Assets | 3.6M | 3.5M | 2.0M | 1.2M | 1.4M | 1.7M | |
Total Liab | 12.9M | 30.5M | 24.5M | 21.9M | 25.2M | 14.9M | |
Net Invested Capital | 57.5M | 61.9M | 35.9M | 14.3M | 16.4M | 15.6M | |
Total Current Assets | 60.7M | 66.6M | 36.9M | 17.6M | 20.3M | 19.3M | |
Net Working Capital | 53.5M | 55.6M | 28.9M | 6.5M | 5.8M | 5.5M | |
Short Term Debt | 863K | 1.6M | 5.7M | 6.5M | 7.4M | 7.8M |
Biomx Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 7K | 699K | 2.1M | 2.4M | 2.8M | 2.9M | |
Operating Income | (30.3M) | 35.5M | (27.2M) | (27.7M) | (24.9M) | (23.7M) | |
Ebit | (30.1M) | (35.5M) | (26.2M) | (23.7M) | (21.3M) | (22.4M) | |
Research Development | 20.9M | 22.7M | 16.2M | 19.0M | 21.9M | 14.7M | |
Income Before Tax | (30.1M) | (36.2M) | (28.3M) | (26.1M) | (23.5M) | (24.7M) | |
Net Income | (29.9M) | (36.2M) | (28.3M) | (26.2M) | (23.6M) | (24.7M) | |
Tax Provision | 3K | 67K | 65K | 61K | 54.9K | 44.2K | |
Net Interest Income | 518K | (620K) | (1.6M) | (1.7M) | (1.5M) | (1.4M) | |
Interest Income | 641K | 86K | 464K | 792K | 712.8K | 506.3K | |
Ebitda | (27.9M) | (32.9M) | (23.7M) | (22.8M) | (20.5M) | (21.6M) | |
Income Tax Expense | (172K) | 67K | 65K | 23K | 26.5K | 27.8K | |
Gross Profit | (2.2M) | (2.6M) | (2.7M) | (1.2M) | (1.1M) | (1.2M) | |
Cost Of Revenue | 2.2M | 2.6M | 2.5M | 871K | 1.0M | 1.9M |
Biomx Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Investments | (9.8M) | 16.2M | (2.1M) | 3.4M | 3.9M | 4.1M | |
Change In Cash | (35.2M) | 25.9M | (30.8M) | (16.4M) | (14.8M) | (14.0M) | |
Depreciation | 2.2M | 2.6M | 2.5M | 871K | 1.0M | 1.2M | |
Capital Expenditures | 1.0M | 3.7M | 112K | 50K | 57.5K | 54.6K | |
Net Income | (30.1M) | (36.2M) | (28.3M) | (26.2M) | (23.6M) | (24.7M) | |
Change To Netincome | 634K | 3.0M | 2.8M | 670K | 770.5K | 1.5M | |
End Period Cash Flow | 37.2M | 63.1M | 32.3M | 15.9M | 18.2M | 27.2M | |
Free Cash Flow | (25.5M) | (31.3M) | (29.2M) | (21.3M) | (19.2M) | (20.2M) | |
Other Non Cash Items | 116K | (276K) | (396K) | 477K | 548.6K | 576.0K |
Biomx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biomx's current stock value. Our valuation model uses many indicators to compare Biomx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomx competition to find correlations between indicators driving Biomx's intrinsic value. More Info.Biomx Inc is considered to be number one stock in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . At present, Biomx's Return On Equity is projected to drop based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Biomx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Biomx Inc Systematic Risk
Biomx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biomx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Biomx Inc correlated with the market. If Beta is less than 0 Biomx generally moves in the opposite direction as compared to the market. If Biomx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biomx Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biomx is generally in the same direction as the market. If Beta > 1 Biomx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biomx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biomx growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Biomx March 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biomx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biomx Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biomx Inc based on widely used predictive technical indicators. In general, we focus on analyzing Biomx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomx's daily price indicators and compare them against related drivers.
Downside Deviation | 6.26 | |||
Information Ratio | 0.0433 | |||
Maximum Drawdown | 36.62 | |||
Value At Risk | (11.29) | |||
Potential Upside | 9.59 |
Complementary Tools for Biomx Stock analysis
When running Biomx's price analysis, check to measure Biomx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomx is operating at the current time. Most of Biomx's value examination focuses on studying past and present price action to predict the probability of Biomx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomx's price. Additionally, you may evaluate how the addition of Biomx to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Bonds Directory Find actively traded corporate debentures issued by US companies |